Literature DB >> 32190308

Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer service.

Andrea Sbrana1, Federico Paolieri1, Francesco Bloise1, Marco Danova2, Luca Galli1, Isa M Brunetti1, Enrico Vasile1, Sergio Ricci1, Alfredo Falcone1, Andrea Antonuzzo1.   

Abstract

Patients with cancer may develop disease- or treatment-associated anemia, requiring red blood product transfusions. In Italy, transfusions are usually administered in a day hospital service or in inpatient wards. Since 2013, a dedicated supportive care service for outpatients has been implemented in Pisa, where red blood product transfusions are administered. The present study evaluated the patients that received red blood product transfusions at the dedicated supportive care service for outpatients in 2016. The clinical features of patients were analyzed, and the procedural cost was evaluated by comparing its administration with a hypothetical scenario in which transfusions were provided via day hospital services or inpatient wards. The results revealed that the dedicated supportive care service for outpatients avoided the hospitalization of patients, allowing them to receive prompt and timely transfusions, with a rapid resolution of symptoms. Avoiding hospitalization was also estimated to decrease transfusion-associated costs by €48,805-177,805.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  anemia; clinical effect; economic effect; outpatient; red cell products; transfusions

Year:  2020        PMID: 32190308      PMCID: PMC7054705          DOI: 10.3892/br.2020.1274

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  12 in total

1.  Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use.

Authors:  D Schrijvers; H De Samblanx; F Roila
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Supportive care and not only palliative care in the route of cancer patients.

Authors:  Andrea Antonuzzo; Maurizio Lucchesi; Isa Maura Brunetti; Luca Galli; Enrico Vasile; Francesca Bonci; Sergio Ricci; Alfredo Falcone
Journal:  Support Care Cancer       Date:  2012-11-15       Impact factor: 3.603

3.  Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review.

Authors:  J J Caro; M Salas; A Ward; G Goss
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

Review 4.  Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols.

Authors:  Rowena N Schwartz
Journal:  Am J Health Syst Pharm       Date:  2007-02-01       Impact factor: 2.637

5.  A supportive care in cancer unit reduces costs and hospitalizations for transfusions in a comprehensive cancer center.

Authors:  Carla Ida Ripamonti; Pietro Molani; Cinzia Desti; Giacomo Boscagli; Fernando Ravagnani; Flavio Arienti; Clementina Di Cristo
Journal:  Tumori       Date:  2017-04-24       Impact factor: 2.098

Review 6.  Anaemia of cancer: impact on patient fatigue and long-term outcome.

Authors:  Peter Harper; Timothy Littlewood
Journal:  Oncology       Date:  2005-10-21       Impact factor: 2.935

Review 7.  Mechanisms of cancer-related fatigue.

Authors:  Julie L Ryan; Jennifer K Carroll; Elizabeth P Ryan; Karen M Mustian; Kevin Fiscella; Gary R Morrow
Journal:  Oncologist       Date:  2007

Review 8.  Anemia management in oncology and hematology.

Authors:  Jerry L Spivak; Pere Gascón; Heinz Ludwig
Journal:  Oncologist       Date:  2009

Review 9.  Prevalence and outcomes of anemia in cancer: a systematic review of the literature.

Authors:  Kevin Knight; Sally Wade; Lodovico Balducci
Journal:  Am J Med       Date:  2004-04-05       Impact factor: 4.965

10.  Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.

Authors:  J L Steegmann; J M Sánchez Torres; R Colomer; Á Vaz; J López; I Jalón; M Provencio; A González-Martín; M Pérez
Journal:  Clin Transl Oncol       Date:  2012-12-19       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.